Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 4/20 | 0.39 |
| ▸ | ARG2 | P78540 | 4/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MELK | Q14680 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655011 | 1.00 | KMT2A (0.48) | KMT2AMEN1LMNAEPHX1SMYD3 | |
| SCHEMBL5967831 | 0.92 | SMYD3 (0.46) | KMT2AMEN1LMNAEPHX1SMYD3 | |
| SCHEMBL15054947 | 0.92 | SMYD3 (0.46) | KMT2AMEN1LMNAEPHX1SMYD3 | |
| SCHEMBL28661580 | 0.92 | SMYD3 (0.46) | KMT2AMEN1LMNAEPHX1SMYD3 | |
| SCHEMBL2735533 | 0.89 | MEN1 (0.40) | KMT2AMEN1LMNAEPHX1SMYD3 | |
| SCHEMBL17690658 | 0.85 | EPHX2 (0.50) | KMT2AMEN1LMNASMYD3XIAP | |
| SCHEMBL17690660 | 0.85 | EPHX2 (0.50) | KMT2AMEN1LMNASMYD3XIAP | |
| SCHEMBL25069101 | 0.85 | EPHX1 (0.43) | EPHX1SMYD3ARG1ARG2DPP4 | |
| SCHEMBL22629584 | 0.85 | EPHX1 (0.50) | KMT2AMEN1LMNAEPHX1SMYD3 | |
| SCHEMBL1953167 | 0.85 | EPHX1 (0.47) | EPHX1DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-02-23 | — | — | US | disclosed |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-02-23 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| US-8088823-B2 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS AG (AT) | 2012-01-03 | — | — | US | disclosed |
| EP-1501495-B1 | USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI | NABRIVA THERAPEUTICS AG (AT) | 2010-09-08 | — | — | EP | disclosed |
| US-7790749-B2 | Use of pleuromutilins for the treatment of disorders caused by Helicobacter pylori | NABRIVA THERAPEUTICS AG (AT) | 2010-09-07 | — | — | US | disclosed |
| US-7790749-B2 | Use of pleuromutilins for the treatment of disorders caused by Helicobacter pylori | NABRIVA THERAPEUTICS AG (AT) | 2010-09-07 | — | — | US | disclosed |
| EP-1875903-B1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | NABRIVA THERAPEUTICS AG (AT) | 2010-07-28 | — | — | EP | disclosed |
| EP-1875903-A1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | Nabriva Therapeutics Forschungs GmbH (AT) | 2008-01-09 | — | — | EP | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | PLEC, TTR, TREH | KMT2A 4575/4885MEN1 559/4885LMNA 1879/4885 |
| US-20120046276-A1 | Tuberculosis treatment using pleuromutilin derivatives | PLEC, TTR, TREH | KMT2A 4575/4885MEN1 559/4885LMNA 1879/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | KMT2A 30/4885MEN1 2603/4885LMNA 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.